Manuel Gordillo, MD
Infectious Disease · Sarasota, FLNPI 1346347887
Payments from drug & device makers
What this record shows
This record is dominated by other: $2,173 of the $3,353 with a category attached, or 64.8%. Cashflow Solutions, LLC accounts for 64.8% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2023 at $2,336 and has fallen 98.0% since, to $46 in 2025.
Across 19 payments — averaging $176.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cashflow Solutions, LLC$2K
- Astellas Pharma US Inc$348
- Organogenesis Inc.$162
- Teva Pharmaceuticals USA, Inc.$125
- Viiv Healthcare Company$125
- Mimedx Group, Inc.$125
- plus $295 from 5 others
Across 160 payments — averaging $13,681 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$2.2M
What the payments were for
- Food & beverage$83225%
- Education$34810%
- Other$2,17365%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cashflow Solutions, LLC | 1 | $2,173 |
| Astellas Pharma US Inc | 4 | $348 |
| Organogenesis Inc. | 3 | $162 |
| Teva Pharmaceuticals USA, Inc. | 1 | $125 |
| Viiv Healthcare Company | 1 | $125 |
| Mimedx Group, Inc. | 1 | $125 |
| Gilead | 1 | $119 |
| Smith+Nephew | 3 | $86 |
| Insmed, Inc. | 2 | $57 |
| AbbVie | 1 | $18 |
| Biomerieux Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Lympha Press Optimal Plus(US) BT$2,173
- PCD-51 731A (US) - White$2,173
- PCD-52 737A (US) White$2,173
- Austedo XR$125
- DOVATO$125
- Apligraf$125
- Epclusa$119
How this compares
$3,353 in reported general payments places this provider in the 75th percentile of 669 infectious disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 85 | $54,562 |
| Cefepime Hcl | 59 | $10,096 |
| Rifabutin | 30 | $7,356 |
| ErtapenemErtapenem Sodium | 12 | $5,320 |
| Meropenem | 18 | $4,088 |
| Ethambutol Hcl | 36 | $2,314 |
| Cephalexin | 38 | $1,835 |
| Vancomycin Hcl | 14 | $1,453 |
| Fluconazole | 14 | $1,107 |
| Doxycycline Hyclate | 37 | $928 |
| CeftriaxoneCeftriaxone Sodium | 20 | $646 |
| Azithromycin | 38 | $582 |
| Cefazolin Sodium | 16 | $537 |
| Clindamycin Hcl | 19 | $396 |
| Amoxicillin | 19 | $280 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Sarasota
- Lennox ArchibaldGainesville$2.1M
- Moti RamgopalFort Pierce$1.1M
- Juan DiazAltamonte Springs$980K
- Charlotte-Paige RolleOrlando$619K
- Kenneth AlexanderOrlando$474K
- Douglas BrustMiami$359K
- Christopher CooperAltamonte Springs$278K
- Federico HinestrosaOrlando$276K
- Cynthia RiveraMiami Beach$265K
- Sally AlrabaaTampa$250K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.